stock-incyte-01-shutter

Incyte’s Pemazyre becomes FDA’s first and only approved unresectable, advanced cholangiocarcinoma treatment

pharmafile | April 20, 2020 | News story | Sales and Marketing FDA, Incyte, pharma 

The FDA has approved the United States’ first and only treatment for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma, a rare form of bile duct cancer, with the marketing authorisation of Incyte’s Pemazyre (pemigatinib).

The kinase inhibitor is approved specifically in adult cholangiocarcinoma patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Incyte scored the approval via the FDA’s Breakthrough Therapy and Orphan Drug designation pathways, sealing the decision after the drug demonstrated a 36% overall response as a monotherapy, meeting its main goal in clinical trials. Furthermore, the drug also met its secondary endpoint, displaying duration of response of 9.1 months.

Incyte CEO Hervé Hoppenot commented on the decision: “Our research into FGFR2 fusions or rearrangements in cholangiocarcinoma and the development of Pemazyre as the first targeted treatment option demonstrates our commitment to translating scientific discovery into solutions that can positively impact patients’ lives. We’re proud to bring Pemazyre to patients and will make this new treatment available immediately.”

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine

The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …

The Gateway to Local Adoption Series

Latest content